Candriam S.C.A. Bei Gene, Ltd. Transaction History

Candriam S.C.A.

$17.1 Billion
Q3 2024

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$125.51 - $229.3 $144,587 - $264,153	1,152 Added 23.6%	6,033 $1.33 Million
Q3 2022 Nov 10, 2022	BUY	$131.8 - $202.24 $205,212 - $314,887	1,557 Added 46.84%	4,881 $658,000
Q4 2021 Feb 10, 2022	SELL	$248.56 - $389.34 $33 Million - $51.8 Million	-132,957 Reduced 97.56%	3,324 $901,000
Q3 2021 Nov 09, 2021	BUY	$249.6 - $403.14 $1.42 Million - $2.29 Million	5,686 Added 4.35%	136,281 $49.5 Million
Q2 2021 Jul 20, 2021	SELL	$292.75 - $367.01 $17.8 Million - $22.3 Million	-60,749 Reduced 31.75%	130,595 $44.8 Million
Q1 2021 Apr 29, 2021	SELL	$260.64 - $382.12 $1,303 - $1,910	-5 Reduced -0.0%	191,344 $47.5 Million
Q4 2020 Jan 22, 2021	BUY	$221.31 - $316.61 $6.01 Million - $8.6 Million	27,152 Added 16.54%	191,349 $49.4 Million
Q3 2020 Oct 19, 2020	SELL	$189.18 - $286.44 $393,305 - $595,508	-2,079 Reduced 1.25%	164,197 $47 Million
Q2 2020 Jul 23, 2020	BUY	$123.9 - $195.41 $5.05 Million - $7.97 Million	40,779 Added 32.49%	166,276 $31.3 Million
Q1 2020 May 26, 2020	BUY	$121.84 - $173.19 $1,340 - $1,905	11 Added 0.01%	125,497 $20.3 Million
Q4 2019 Jan 21, 2020	SELL	$115.78 - $208.34 $5.82 Million - $10.5 Million	-50,266 Reduced 28.6%	125,486 $21,000
Q3 2019 Oct 21, 2019	SELL	$120.61 - $148.29 $7 Million - $8.6 Million	-58,000 Reduced 24.81%	175,752 $22,000
Q2 2019 Aug 01, 2019	BUY	$113.99 - $146.86 $5.76 Million - $7.42 Million	50,520 Added 27.57%	233,752 $28.8 Million
Q1 2019 May 02, 2019	BUY	$122.82 - $151.83 $4.35 Million - $5.38 Million	35,444 Added 23.98%	183,232 $24.2 Million
Q4 2018 Feb 14, 2019	BUY	$107.01 - $175.15 $5.08 Million - $8.32 Million	47,488 Added 47.35%	147,788 $20.7 Million
Q3 2018 Nov 07, 2018	BUY	$152.62 - $189.66 $8.97 Million - $11.2 Million	58,800 Added 141.69%	100,300 $17.3 Million
Q2 2018 Aug 14, 2018	BUY	$152.5 - $216.77 $991,250 - $1.41 Million	6,500 Added 18.57%	41,500 $6.38 Million
Q1 2018 May 09, 2018	BUY	$97.41 - $177.22 $3.41 Million - $6.2 Million	35,000 New	35,000 $5.88 Million

Others Institutions Holding BGNE

# of Institutions

252

Shares Held

45.3M

Call Options Held

292K

Put Options Held

119K

Baker Bros. Advisors LP New York, NY

10.6M
Shares

$1.91 Billion
25.41% of portfolio
Capital International Investors Los Angeles, CA

6.43M
Shares

$1.16 Billion
0.29% of portfolio
Hhlr Advisors, Ltd. Grand Cayman, E9

5.18M
Shares

$935 Million
26.65% of portfolio
Primecap Management CO Pasadena, CA

4.97M
Shares

$899 Million
0.84% of portfolio
Baillie Gifford & CO

3.71M
Shares

$669 Million
0.64% of portfolio

View Full List

About BeiGene, Ltd.

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.7B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

More about BGNE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

News

Stay updated on Candriam S.C.A. with notifications on news.

Account